Individual patients' risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab
- PMID: 33713786
- DOI: 10.1016/j.jaad.2021.03.018
Individual patients' risk factors impact guidelines for prophylactic agents used in pemphigus patients treated with rituximab
Conflict of interest statement
Conflicts of interest The authors have been investigators/advisory board members for Roche and for rituximab clinical trials.
Comment on
-
Diagnosis and management of pemphigus: Recommendations of an international panel of experts.J Am Acad Dermatol. 2020 Mar;82(3):575-585.e1. doi: 10.1016/j.jaad.2018.02.021. Epub 2018 Feb 10. J Am Acad Dermatol. 2020. PMID: 29438767 Free PMC article.
-
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV).J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1900-1913. doi: 10.1111/jdv.16752. Epub 2020 Aug 24. J Eur Acad Dermatol Venereol. 2020. PMID: 32830877
-
Pemphigus management guidelines: A life-saving perspective.J Am Acad Dermatol. 2021 Jul;85(1):e45-e46. doi: 10.1016/j.jaad.2021.01.105. Epub 2021 Mar 10. J Am Acad Dermatol. 2021. PMID: 33713787 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
